Tumor Biology · 2015 · 39 citations · 26 references
MedicineDermatologyOncologyCarcinogenesisCutaneous OncologyMolecular OncologyAngiogenesisAngiogenesis In CancerMelanocytic TumorsMolecular Tumor ProfilingStaging Of Skin CancerTumor MarkersCutaneous Melanoma StagingDisease-free Survival AssessmentMelanoma BiomarkersPrognostic Factors AnalysisPrognostic IndicesRecurrence-free SurvivalSerum Tumor MarkersVascular Endothelial Growth Factor
The identification of prognostic factors in cutaneous melanoma allows choosing the most effective treatment, especially in group of patients with locoregional disease. Markers related to carcinogenesis and angiogenesis in particular have effect on the course of the disease. The aim of this study was to evaluate clinical utility of vascular endothelial growth factor (VEGF), matrix metalloproteinase 2 (MMP-2), MMP-9, tissue inhibitors of metalloproteinase 1 (TIMP-1), and YKL-40 in serum of melanoma patients at pathological stages I-III. We included 148 adult patients with melanoma. The median follow-up was 40 months. Disease recurrence was observed in 43 patients; 3-year disease-free survival (DFS) rate was 71.7%; 35 patients died; and the 3-year overall survival (OS) rate was 85%. Concentrations of VEGF, MMP-2, MMP-9, TIMP-1, and YKL-40 were measured by ELISA kits. VEGF, MMP-9, TIMP-1, and YKL-40 were significantly higher in group of patients than in controls. Increased concentrations of TIMP-1 were related to patient survival, which in the group of lower and increased TIMP-1, disease-free survival amounted to 81 vs. 61% (p = 0.014) and overall survival -88 vs. 82% (p = 0.050), respectively. An increased concentration of YKL-40 was observed in 59% of patients with ulceration and in 26% of patients without ulceration (p = 0.012). We have found a clinically significant correlation between YKL-40 and MMP-9 (rho = 0.363; p = 0.004) as well as YKL-40 and VEGF (rho = 0.306; p = 0.018). In melanoma patients at stages I-III, the high concentrations of TIMP-1 in serum predicted adverse prognosis. YKL-40 was associated with ulceration of primary tumor, which is a very important prognostic factor.
26
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch, Jeffrey E. Gershenwald, Seng-Jaw Soong et al. · Journal of Clinical Oncology · 2009 · 4.6K citations · Full text
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Reinhard Dummer, Axel Hauschild, Merlin Guggenheim et al. · Annals of Oncology · 2012 · 717 citations · Full text
Medicine, Dermatology, Oncology +14
YKL-40, a secreted glycoprotein, promotes tumor angiogenesis
Rong Shao, Katie Hamel, Louise Munkhaus Petersen et al. · Oncogene · 2009 · 292 citations · Full text
Johanna Nikkola, Pia Vihinen, Meri‐Sisko Vuoristo et al. · Clinical Cancer Research · 2005 · 196 citations · Full text
Early Detection and Prognosis of Ovarian Cancer Using Serum YKL-40
Jakob Dupont, Meena K. Tanwar, Howard T. Thaler et al. · Journal of Clinical Oncology · 2004 · 137 citations · Full text
Medicine, Gynecology, Oncology +17